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Abstract
Dendritic cells (DCs) play a key role in initiating adaptive immune response by presenting antigen to T cells in lymphoid
organs. Here, we investigate the potential of quantum dots (QDs) as fluorescent nanoparticles for in vitro and in vivo
imaging of DCs, and as a particle-based antigen-delivery system to enhance DC-mediated immune responses. We used
confocal, two-photon, and electron microscopies to visualize QD uptake into DCs and compared CD69 expression, T cell
proliferation, and IFN-c production by DO11.10 and OT-II T cells in vivo in response to free antigen or antigen-conjugated to
QDs. CD11c
+ DCs avidly and preferentially endocytosed QDs, initially into small vesicles near the plasma membrane by an
actin-dependent mechanism. Within 10 min DCs contained vesicles of varying size, motion, and brightness distributed
throughout the cytoplasm. At later times, endocytosed QDs were compartmentalized inside lysosomes. LPS-induced
maturation of DCs reduced the rate of endocytosis and the proportion of cells taking up QDs. Following subcutaneous
injection of QDs in an adjuvant depot, DCs that had endocytosed QDs were visualized up to 400 mm deep within draining
lymph nodes. When antigen-conjugated QDs were used, T cells formed stable clusters in contact with DCs. Antigen-
conjugated QDs induced CD69 expression, T cell proliferation, and IFN-c production in vivo with greater efficiency than
equivalent amounts of free antigen. These results establish QDs as a versatile platform for immunoimaging of dendritic cells
and as an efficient nanoparticle-based antigen delivery system for priming an immune response.
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Introduction
As professional antigen-presenting cells of the immune-system,
DCs are instrumental in the initiation of adaptive immunity by
presenting antigen to T cells [1]. Immature DCs endocytose
soluble molecules and particulate material from the surrounding
medium via macropinocytosis and adsorptive endocytosis, and
then migrate from peripheral tissues to draining lymph nodes [2].
Antigenic proteins are processed into peptides, and loaded to
major histocompatibility (MHC) molecules class I and class II. In
immature DCs, MHC-II is present in late endosomes or lysosomes
[2–5]. However, with time, MHC-II molecules are trafficked via
class-II vesicles towards the plasma membrane, where the pMHC-
II is presented to T cells [4]. DC maturation, characterized by
reduced endocytosis and by upregulation of the cell-surface
activation markers CD80 and CD86, is promoted by ‘‘danger’’
signals or ligands for toll-like receptors [6]. Although the chemistry
and subcellular distribution of compartments related to the
antigen-presentation pathway in DCs have been studied exten-
sively, the real-time dynamics of early endocytic vesicles in DCs
have not yet been characterized.
Previous investigations have established two-photon microscopy
as an elegant method for imaging deep inside a living tissue or
organ for long periods (hours) [7]. The spatial and temporal
resolution achieved by two-photon microscopy is unparalleled by
other methods of non-optical deep-tissue imaging, including PET
and FMRI [8]. Previous imaging studies in the lymph node
utilizing fluorescent ‘cell-tracker’ dyes have visualized skin-
draining DCs carrying cognate antigen, and the associated
dynamic changes in T cell motility induced by DC contact [9–
12]. Initially, T cells make transient contacts (stochastic scanning)
with antigen-presenting DCs, and their behavior then progresses
from serial interactions to formation of dynamic T cell clusters, T
cell dissociation and swarming, leading ultimately to several
rounds of T cell proliferation.
Quantum dots (QDs) are semiconductor nanocrystals that
exhibit very bright and photostable fluorescence. QDs have broad
absorption spectra, and narrow Gaussian emission spectra with
peak emission wavelengths that depend upon their size [13,14].
They are available encapsulated with biopolymeric coatings that
allow conjugation with biomolecular moieties, and have been used
for imaging in several in vitro and in vivo biological systems [13,15–
17]. When observed by two-photon microscopy QD fluorescence
is 100–1,000 times brighter than conventional fluorophores, and is
maintained for long periods of time without photobleaching.
Proteins can be stably conjugated to the surface of encapsulated
QDs by charge-charge interaction, or by using linkers such as
streptavidin and maltose-binding protein. In addition to fluores-
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3290cence imaging, individual QDs can be observed using electron
microscopy, and correlated with fluorescence microscopy [18–20].
Although QDs have been used for high-resolution imaging in
biological systems, they have not yet been used for simultaneous
modulation of biological function.
We have harnessed the fluorescence and bioconjugation potential
of QDs for real-time imaging of dendritic cells (DCs) in vitro,f o rd e e p
tissue imaging of DCs in vivo, and for concomitant modulation of
DCs to elicit an immune response to a specific antigen both in vitro
and in vivo. The broad excitation spectra and narrow emission
spectraofQDsmakethemideallysuitedfortwo-photonfluorescence
excitation and color separation from other probes. In addition, the
hightwo-photoncross-sectionofQDsgreatlyincreasestheirsignalto
noise ratioas compared to fluorescentproteins.These twoproperties
facilitate detection of QD labeled cells by two-photon microscopy
during real-time tissue imaging. Moreover, the ability to conjugate
QDs with bioactive proteins makes them potentially useful for
modulating biological responses and for cell tracking. Here, we first
illustrate the use of QDs for in vitro imaging of intracellular
compartments inside DCs following endocytosis. We then demon-
strate that QDs facilitate real-time tissue imaging of DCs inside the
lymph node. Finally, we show that quantum dots can be used
effectively as a particle-based antigen delivery system, employing
specific antigenic proteins conjugated to QDs to trigger T cell
activation with high efficiency in two transgenic TCR models.
Results
Quantum dot uptake by dendritic cells
Murine DCs derived from bone marrow avidly endocytosed
streptavidin-conjugated or unconjugated QDs during imaging in
vitro at 37uC. QDs differing in size from 15–20 nm were taken up
at approximately the same rate (not shown), and were retained for
at least 48 hr without toxicity (Figure S1). In these mixed cultures,
cells that became brightly labeled by taking up QDs also exhibited
dynamic dendritic processes (Figure 1A; Video S1), whereas the
smaller, round cells (presumptive monocytes) did not take up QDs.
Flow cytometric analysis showed that QD
+ cells also expressed the
characteristic DC marker CD11c (Figure S2). Furthermore, in
experiments on bone marrow-derived cells cultured from EYFP-
CD11c reporter mice, EYFP
+ DCs became brightly labeled with
endocytosed QDs (Figure 1B). Together, these results show that
QDs are avidly and preferentially taken up by CD11c
+ DCs.
We monitored the kinetics of QD uptake following addition of
QDs to the bathing medium (Figure 2A–2F; Video S2). QD-
fluorescence appeared within 2 min as a band adjacent to the
plasma membrane of DCs (Figure 2A and 2D). Subsequently,
distinct QD-containing vesicles were apparent inside the cells,
initially close to the plasma membrane (Figure 2B and 2E), and
later throughout the cytoplasm (Figure 2C and 2F). At longer
times, the number of QD-containing vesicles per cell increased, as
did their size and fluorescence intensity. Close inspection of single
cells showed individual vesicles of varying size (up to ,1 mmi n
diameter) ‘jiggling’ in the cytoplasm. Occasionally, vesicles fused
with one another inside the cell (Figure 2G–2I; Video S3), but
vesicle fusion with the plasma membrane or release of their
contents was never observed. Individual vesicles moved in a ‘‘stop
and go’’ manner, exhibiting occasional bursts of high velocity
followed by periods of jiggling (Figure 2J and 2K; Video S4). The
mean vesicular velocity was 961.5 mm/min at 37uC, whereas
peak velocities during bursts were 5–10 times faster. Vesicular
velocities were independent of the apparent variation in vesicular
sizes. Vesicles did not exhibit any directional preference in their
motion, as shown by their trajectories (Figure 2L). Increased
temperature reversibly increased vesicular velocities (Figure 2M;
Video S4) with a Q10 of ,2. The rate of endocytosis is known to
slow following maturation of DCs [2]; and, consistent with this, we
observed a dramatically (10-fold) reduced rate of quantum dot
uptake in DCs matured by treatment with LPS (Figure 2N). QD
uptake was observed in a greater proportion of cells in the
immature-DC population compared to matured DCs (Data not
shown). The number of QD-containing vesicles was reduced in
LPS-treated DCs. However, velocities and subcellular kinetics of
vesicles was not altered.
To investigate the involvement of cytoskeletal elements on QD
uptake and vesicle dynamics, we observed effects of pre-treatment
and acute addition of cytochalasin D, calyculin A, or nocodazole
in DCs (Figure 3). Untreated control DCs displayed QD-
containing vesicles, as well as intact actin filaments (Figures 3A–
3C and S3A–S3C). Actin filaments were absent inside cytochalasin
D-treated DCs, whereas patches of condensed actin were observed
near the plasma membrane along with vesicles that contained QD
(Figure S3D–S3F), and total uptake of QD was partially inhibited
(Figure 3D–3F, 3M). Inside nocodazole-treated DCs actin
filaments were intact and QD-containing vesicles were apparent,
as in untreated DCs (Figures 3G–3I and S3G–S3I). Nocodazole-
Figure 1. DCs avidly endocytose QDs. (A) Overlay of brightfield and fluorescent images showing endocytosed QD-655 (red) within DCs with
dendritic processes (indicated by arrows), after 30 min of incubation of DCs in QD-containing medium. Image is a single frame from Video S1. Scale
bar=10 mm. (B) Two-photon image showing endocytosed QDs (red) inside CD11c
+ DCs (green) cultured from bone marrow of transgenic EYFP-
CD11c reporter mice. Scale bar=5 mm.
doi:10.1371/journal.pone.0003290.g001
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again partially reduced compared to untreated DCs (Figure 3M).
Calyculin A-treated DCs rounded up, and cortical actin was
observed condensed near the periphery (Figure S3J). QD-uptake
was abolished in most calyculin A-treated DCs (Figure 3J–3M, S3J–
S3L). When present, QD fluorescence was restricted to the cell
perimeter. However, deeper intracellular QD-containing vesicles
werenotformed.Together,theseresultsindicatethat thepresenceof
free cortical actin is necessary for QD-uptake by DCs.
We next studied the effects of these cytoskeletal inhibitors on the
dynamics of QD-containing vesicles within DCs. Cytochalasin D
did not affect vesicular dynamics (Figure 3O, Video S5). However,
nocodazole produced vesicle arrest (Figure 3P, Video S6),
implying that microtubular assembly is necessary for motion of
individual vesicles inside DCs. Moreover, in untreated DCs,
vesicles did not freely diffuse inside the cytoplasm, but exhibited
constrained ‘‘jiggling’’ movement (Video S4), consistent with an
attachment to microtubules. Calyculin A did not inhibit vesicular
Figure 2. Dynamics of QD-uptake and QD-containing vesicles. (A–F) Two-photon images of QD uptake by DCs at ,2 min, 9 min, and 18 min
after beginning incubation with 2 nM QD-containing medium at 37uC. These frames have been taken from from Video S2. Indicated areas of A–C are
magnifiedinD–F respectively toshowindividual vesicles.Scale bars=10 mminA– C ,an d=1mm inD–F.(G–I) FusionofQD-containingvesiclesinside DCs.
Three vesicles, indicated by arrows, come closer, and eventually fuse into a single larger vesicle. These frames have been taken from Video S3. Scale
bars=2 mm. (J) DCs with QD-containing. The image is a single frame taken from Video S4. Scale bar=4 mm. Arrowheads with numbers represent three
individual vesicles, whose velocities are shown in K. (K) Velocity profiles of the individual vesicles indicated by numbers in J. Velocity bursts (with peak
velocities .5 times the average velocity) are marked in gray. (L) Trajectories of 10 individual vesicles that could be tracked for .140 sec, normalized to
their starting coordinates. (M) Temperature-dependence of vesicular velocities in DCs. Data from 3 independent experiments, 10–12 vesicles per
experiment. (N) Downregulation of rate of QD-uptake by DC maturation. Plot of normalized mean QD-fluorescence intensity over time for LPS-treated or
mature(diamonds)anduntreatedorimmature(squares)DCs.Linesarelinearregressions,withslopesof32.8610
24a.u./s for immature cells and 4.4610
24
a.u./s for mature cells. Data from 4 independent experiments for each condition, 6–10 cells per experiment.
doi:10.1371/journal.pone.0003290.g002
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PLoS ONE | www.plosone.org 3 September 2008 | Volume 3 | Issue 9 | e3290Figure 3. Effects of cytoskeletal inhibitors on QD-endocytosis by DCs. QD (red) uptake in untreated control DCs (A–C), or DCs treated with
cytochalasin D (D–F), nocodazole (G–I), or calyculin A (J–L). Scale bar=10 mm. (M) Histogram showing mean normalized QD-fluorescence intensity of
cells treated under different conditions as indicated. QD-fluorescence intensity has been expressed as a ratio of the mean QD-fluorescence intensity
of untreated DCs. (N–Q) Trajectories of QD-containing vesicles inside untreated control DCs (N), or acutely treated with 1 mM cytochalasin D (O), 1 mM
nocodazole (P), or 200 nM calyculin A (Q), respectively. The effects of these reagents on the dynamics of QD-containing vesicles inside DCs is further
illustrated in Video S5, S6 and S7.
doi:10.1371/journal.pone.0003290.g003
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vesicles were occasionally observed to traverse longer paths
compared to untreated DCs, indicating the absence of interactions
with actin for relatively longer periods of time.
Compartmentalization of endocytosed QDs
Co-labeling of QD-containing DCs for the lysosomal protein
LAMP-2 showed that QD-containing vesicles (within 0–5 min of
incubation) did not colocalize with lysosomes initially (Figure 4A–
4I). However, at later time points (.,45 min) an increasing
number of QD-containing vesicles colocalized with lysosomes
(Figure 4J–4O), indicating that eventually QDs are retained inside
lysosomes. We also visualized the distribution of single QDs inside
DCs by electron microscopy (Figure 4P–4U). QD-containing
vesicles were localized near the plasma membrane after 5 min of
incubation (Figure 4P and 4Q); at this time vesicles typically
contained ,5–6 QDs and had sizes ,500 nm. After 45 min of
incubation the numbers of QD-containing vesicles increased, each
containing ,20–30 QDs, with sizes up to 1000 nm (Figure 4R
and 4S). Vesicles of varying size were distributed throughout the
cytoplasm. As expected, QDs were excluded from the nuclei and
mitochondria. Together, light microscopy and em visualization
indicate that DCs continually endocytose QDs into small vesicles
that subsequently fuse to form larger vesicles that at later times
mature into lysosomes with higher electron density containing
,50–100 QDs (Figure 4T and 4U).
In vivo labeling of DCs and trafficking to peripheral
lymph nodes
Based on our in vitro results and previous in vivo labeling of DCs
with cell tracker dyes at an adjuvant depot [10], we anticipated
that skin-resident DCs would take up subcutaneously injected QDs
and subsequently traffic into draining lymph nodes. We injected
mice subcutaneously with QD in complete Freund’s adjuvant,
either in eYFP-CD11c reporter mice or in BALB/c mice together
with CFSE, and evaluated subsequent QD together with YFP or
Figure 4. Compartmentation of single QDs inside endocytic vesicles and lysosomes. (A–O) Confocal images showing colocalization of QD-
containing vesicles with the lysosomal protein LAMP-2 inside bone marrow-derived DCs after different times of incubation in QD-containing medium
as indicated on the left. Columns show LAMP-2 staining (green), QD staining (red), and overlays of LAMP-2 and QD images, respectively. Scale bar in
A–O=10 mm. (P–U) Electron mircographs showing individual QDs within DCs, and associated structures and location after different times of
incubation in QD-containing media as indicated on the right.. Indicated regions in P, R, and T, respectively, shown at higher magnification. Note the
correspondence between electron micrographs P, R, and T with confocal images I, L and O, respectively. Scale bars in P, R, and T=1 mm and in Q, S,
and U=200 nm.
doi:10.1371/journal.pone.0003290.g004
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early for skin-draining DCs to arrive in draining lymph nodes,
QDs were observed in the lymph-node subcapsular sinus, but not
inside the cortex (Figure S4). This is expected, as streptavidin-
conjugated QDs have a size ,2000 kD, larger than the
approximate cutoff of ,70 kD for free diffusion into the cortex
from the subcapsular sinus [21]. QDs were also observed inside
eYFP-expressing resident DCs lining the subcapsular sinus. One
day after injection, DCs that had taken up either CFSE or QD, or
both, were distributed within the T cell cortical region, and were
excluded from the follicle (Figure 5A–5C). Flow cytometric
analysis showed that QDs, as well as CFSE, preferentially labeled
CD11c
+ DCs (Figure S5A and S5B). Lymph node DCs labeled
with QDs represent a mixture of migratory and resident DCs
(Figure S5C), as indicated by the distribution of CD8a. Thus,
consistent with our in vitro findings, skin-resident DCs near the site
of injection take up QDs; and in addition, QDs that had migrated
via lymphatics to the draining lymph node, are taken up by lymph
node-resident DCs. The injected fluorophores also labeled a small
percentage of GR-1
+ granulocytes (Figure S5D and S5E). CFSE
labeling of lymph node DCs was uniform through the cell body
and processes, whereas QDs appeared compartmentalized in the
cell body. DCs moved with an average velocity of ,4 mm/min
within the node, with individual DCs showing mean velocities
distributed between 2–8 mm/min (Figure 5D). DCs frequently
changed direction as they moved and did not exhibit any
particular directional preference (Figure 5E). Movements were
generally led by dynamic dendritic processes, followed by the cell
body which often extended cytoplasmic ‘‘tails’’ (Video S8 and S9).
Both CSFE and QD fluorescence could be resolved at depths
down to ,200 mm beneath the capsule, but only QD fluorescence
remained visible below this, at depths up to 400 mm (data not
shown). All QD
+ cells were also CFSE
+ (Figure 5F); thus QDs
enabled deeper imaging by being brighter than CFSE under two-
photon excitation.
Antigen-conjugated QDs potently activate T cells in vitro
and in vivo
To explore the potential use of QDs for particle-based antigen
presentation, we measured the in vitro proliferation of TCR-
transgenic ovalbumin-specific T cells in the presence of bone
marrow-derived DCs pulsed with ovalbumin or ovalbumin-
conjugated QDs (QD
ova) (Figure 6A and 6B, respectively). Both
treatments induced robust proliferation, whereas DCs pulsed with
QDs alone failed to activate T cells (Figure 6C). Quantification of
T cell proliferation using an activation index (AI; see Methods),
revealed that QD
ova was ,20 fold more effective in activating ova-
specific T cells compared to equivalent amounts of free ovalbumin
(Figure 6D). T cell activation plateaued at ovalbumin concentra-
tions .50 mg/ml, and at QD
ova concentrations equivalent to
.1.25 mg/ml ovalbumin. Moreover, the maximal proliferation
was higher with QD
ova than with ovalbumin alone.
We examined dynamic T cell / DC interactions in mice bearing
adoptively transferred ova-specific T cells with and without
immunization with QD
ova. In mice injected with QDs without
ova, T cells migrated freely, interacting transiently with DCs and
covering a broad territory, as indicated by time overlays of
superimposed frames (Figure 7A; Video S10). In contrast, clusters
of T cells were observed surrounding QD
ova-bearing DCs within
draining lymph nodes from mice immunized with QD
ova
Figure 5. QD-labeled DCs visualized in situ in murine lymph nodes. (A–C) Sequential two-photon images of in situ-labeled DCs inside
draining lymph nodes 24 hr after subcutaneous injection of CFSE (green) and QD (red) included in CFA. The time elapsed (min) after beginning
imaging is indicated. The images were taken from Video S8. Scale bar=20 mm. (D) Velocity distribution of DCs in lymph nodes. Arrow indicates
average velocity (4.361.2 mm/min). (E) Trajectories of DCs in lymph nodes, normalized to their starting coordinates. (F) Profiles of CFSE
+ and QD
+ cells
in draining lymph. Percentage of cells (except double negatives) have been indicated on the figure.
doi:10.1371/journal.pone.0003290.g005
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tracks corresponded with red tracks of QD
ova-bearing DCs. These
T cell-DC clusters were observed at depths up to 150 mm. These
results show that antigen-conjugated QD-labeled DCs can
functionally engage in prolonged interactions with antigen-specific
T cells to initiate an immune response.
To assess the ability of QD
ova to induce T cell proliferation in
vivo, CFSE-labeled ova-specific T cells were adoptively into mice
that were then immunized with either ovalbumin or QD
ova. Upon
immunization of these mice with ovalbumin and complete
Freund’s adjuvant (CFA), ova-specific T cells inside draining
lymph nodes divided up to five times within 2 days (Figure 7C–7E;
Figure S6A). Beginning ,3 days after immunization, T cells that
had divided were released into the circulation and were recovered
from the spleen and non-draining lymph nodes (Figure S6). Ova-
specific T cells also proliferated robustly upon immunization of
mice with QD
ova (7F–7H). Assessment of relative in vivo T cell
proliferation prior to T cell egress showed that QD
ova was .5 fold
more effective than free ovalbumin in inducing ova-specific T cell
proliferation (Figure 7I). T cells did not proliferate when injected
with QDs (without antigen) or CFA alone (data not shown).
To evaluate the generality of T cell priming by QD
ova,w e
examined a second transgenic TCR mouse also having sensitivity
to ova but on an entirely different MHC background. To examine
different stages of T cell activation, we evaluated CD69 expression
and production of IFN-c, in addition to cell proliferation (Figure 8).
CD69 expression was up-regulated to a similar extent in mice
immunized with either free ovalbumin+CFA or QD
ova+CFA
(Figure 8 A–C). QD
ova stimulated OT-II T cells to proliferate in
C57BL/6 recipient mice (I-A
b) more efficiently compared to free
ovalbumin (Figure 8D–8I). Furthermore, production of IFN-c was
strongly enhanced in T cells inside draining lymph nodes of mice
immunized with QD
ova, compared to mice immunized with free
ovalbumin (Figure 8K and 8J). Collectively, these results
demonstrate that in vivo T cell priming is more effective using
antigen-conjugated QDs compared to a standard immunization
regimen with free antigen.
Discussion
Our results demonstrate the utility of QDs for functional
immuno-imaging of DCs and concomitant priming of T cell
responses in vitro and in vivo. DCs were shown preferentially to
acquire QDs by endocytosis; single-vesicle dynamics were tracked
inside the cell as small endocytic vesicles jiggled and fused to form
larger vesicles up to 1 mm in diameter. Single QDs were detected
by electron microscopy inside endocytic vesicles that become
increasingly electron dense during maturation. Rates of quantum
dot uptake were reduced during toll-like receptor stimulation with
LPS, consistent with a decrease in the rate of endocytosis during
DC maturation. When included in a subcutaneous adjuvant depot,
QDs were taken up by dendritic cells that migrated into the
draining lymph node, where the bright and stable fluorescence of
QDs facilitated two-photon imaging of DCs with detection limits
at approximately twice the depth as other labels, although not
revealing the dynamics of dendritic processes. Moreover, QDs
bearing conjugated antigen were taken up by DCs and efficiently
evoked T cell proliferative responses in vitro and in vivo.
DCs continually endocytose substances from the surrounding
medium [2]. Previously, QDs have been used for real-time
measurement of receptor-mediated endocytosis in transfected
CHO cells [22]. Human DCs were recently reported to take up
QDs conjugated to a ligand for the specific DC-receptor DC-
SIGN by endocytosis of QDs [15]. In our study, we show that DCs
avidly take up unconjugated or antigen-conjugated QDs, but
without a requirement for conjugated endocytic DC cell-surface
receptor-specific ligands. At a subcellular level, QD-uptake by
DCs was not dependent on microfilaments, since disruption of F-
actin by cytochalasin D did not inhibit uptake, consistent with
previous reports showing that cytochalasin D does not inhibit
endocytosis in mammalian macrophages and leukocytes [23,24].
Endocytosis of small particles (,100 nm) by mammalian macro-
phages have been shown to be insensitive to cytochalasin D
[25,26], and the hydrodynamic diameter of QDs (,20 nm) falls
well below this cutoff. Moreover, cytochalasin is known to inhibit
phagocytosis but not pinocytosis [27]. QD uptake by DCs was not
completely inhibited by nocodazole, indicating the existence of a
microtubule-independent mechanism of QD uptake. Previous
evidence shows that nocodazole does not inhibit endocytosis in
bone marrow-derived phagocytes [28]. In contrast, polymerization
of cortical actin by calyculin A completely inhibited QD uptake by
DCs. Similar inhibition of endocytosis by calyculin A has been
previously observed in T cells [23]. Together, these results indicate
that QDs are endocytosed by DCs mainly via pinocytosis, and the
presence of free actin is necessary for QD uptake. Endocytosed
QDs are compartmentalized by DCs into vesicles. These QD-
Figure 6. Activation of DO11.10 T cells in vitro by DCs pulsed with ovalbumin or QD
ova. (A, B, and C) CFSE peaks representing consecutive
cycles of division of CFSE-labeled T cells that were activated by DCs pulsed with 25 mg/ml ovalbumin (A), 5 nM QD
ova (2.5 mg/ml ovalbumin) (B), or
QD alone (Streptavidin-conjugated QDs without ovalbumin) (C). Lines delineate sequential divisions M1–M7 used in Equation 1 to derive the
activation index (see Methods). The amount of free ovalbumin present in the QD
ova sample was limited by serial dilution to ,0.1 mg/ml during
purification, and was insufficient to induce T cell activation and proliferation (not shown). (D) Normalized activation indices of T cell proliferation as
functions of concentration of ovalbumin (diamonds) and QD
ova (squares). Data from at least 3 independent experiments for each of 6 different QD
and QD
ova concentrations are presented.
doi:10.1371/journal.pone.0003290.g006
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and stationary ‘jiggling’. Endosomes are known to traffic along
microtubules and can interact with actin via motor proteins
[29,30]. Thus, as expected, vesicular motion was arrested by
microtubule disruption using nocodazole. The periods of jiggling
likely represent interactions of QD-containing endosomes with
actin while trafficking along microtubules. Moreover, the absence
of free actin in calyculin A-treated DCs probably caused vesicles to
move freely along microtubles for long distances (Video S7).
Eventually, endocytosed QDs are retained by DCs inside
lysosomes for at least 48 hr.
Previous studies to visualize DCs in vivo have employed
conventional fluorophores and fluorescent proteins, including in
vivo labeling with cell tracker dyes included in alum adjuvant
mixture [10], in vitro labeling with subsequent cell transfer
[11,31,32], microinjection of fluorophores into lymph node [33],
and expression of YFP driven by a CD11c promoter element in
transgenic mice [34]. Here, we show that QDs are selectively
taken up by dendritic cells in vivo, and can be used as a fluorescent
marker for antigen-bearing DCs that traffic to draining lymph
nodes from the site of immunization. Moreover, QD-bearing DCs
can be imaged to greater depth inside draining lymph nodes
without phototoxicity to the tissue. Thus, although not revealing
the dynamics of DC dendrites, QDs are superior to commonly
used fluorophores in terms of imaging depth in intact tissue.
Particle-based antigen delivery systems are being investigated
for the development of efficient DC-based vaccines [35,36]. In
addition to using QDs for imaging of DCs, we further demonstrate
that antigen-conjugated QDs can induce robust DC-mediated
CD4
+ T cell proliferation both in vitro and in vivo in two different
Figure 7. Activation of DO11.10 T cells in vivo by DCs pulsed with QD
ova. Overlays of successive two-photon images of draining lymph
nodes 8 hr after adoptive transfer of CMAC-labeled ova-specific T cells into mice immunized with QD (A) or QD
ova (B) included in 50 ml CFA. These
images are single frames from Video S10 and S11, respectively. Scale bars=20 mm. (C–H) Flow cytometry profiles showing activation of naı ¨ve T cells
in draining lymph nodes of mice, into which ,4610
6 CFSE-labeled ova-specific T cells were adoptively transferred, and which were subsequently s.c.
injected in the lower flank with varying doses of free ovalbumin (C–E, light gray), or ovalbumin conjugated to QDs (dark gray) included in 50 ml CFA.
(I) Normalized activation index as a function of total amount of ovalbumin delivered either unconjugated (diamonds) or conjugated with QDs
(squares). Data are representative of at least 3 independent experiments.
doi:10.1371/journal.pone.0003290.g007
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5–20 fold shift in the dose required to stimulate proliferation and a
strong enhancement of IFN-c production, compared to a standard
immunization using equivalent amounts of free antigen (ovalbumin).
Since QDs are avidly endocytosed by DCs, conjugation to QDs
likely increases the rate of antigen uptake by DCs as compared to
free antigen. The ovalbuminbound to QD is subsequently processed
by the DCs and presented to T cells, whereas the QDs themselves
are not processed by lysosomal enzymes or trafficked further into the
MHC class-II pathway, but are instead retained inside DCs.
Concentrations (5–10 nM) of QDs sufficient to induce robust T cell
proliferation did not produce any evident toxic effects in DCs
observed over a period of 48 hr, and QD
+ cells migrated to the
lymph node 12–16 hr after subcutaneous injection, consistent with
previousstudies showing that QDscan be usedfor several days invivo
without deleterious effects [37,38].
In conclusion, QDs can serve as multi-functional probes with
unique advantages for both imaging studies employing correlated
fluorescence and electron microscopy, and as a potent particle-
based system for antigen delivery. QDs are versatile fluorophores
that can be used to fine-tune important functional aspects of the
immune system, in conjunction with correlated fluorescence and
electron microscopy, and may have potential for use in





b), and congenic CD45.1-





+) were progeny of homozygotic DO11.10
parents purchased from Jackson Laboratory. Ova peptide
323–339/I-
A
b-specific TCR-transgenic OT-II mice were progeny of homo-
zygotic OT-II parents purchased from Jackson Laboratory. Mice
expressing enhanced yellow fluorescent protein (EYFP) on CD11c
promoter were a kind gift from M. Nussensweig [34]. These mice
were back-crossed for 10 generations to a C57BL/6 background.
Mice were housed in a pathogen-free animal facility and all
procedures were performed in accordance with protocols approved
by the institutional animal care and use committee of UCI.
Conjugation of ovalbumin to quantum dots
Ovalbumin was biotinylated using EZ-Link
TM Sulfo-NHS-
Biotin (Pierce
TM). Excess biotin and salts were separated by gel
filtration using D-Salt
TM dextran desalting columns (Pierce
TM).
Biotinylation of ovalbumin was verified by Western blotting.
Quantum dot (QD) 655-streptavidin conjugates (100 nmol;
Quantum Dot Corp./Invitrogen
TM) were mixed with biotinylated
ovalbumin at a molar ratio of 1:10 in 2 ml PBS at 6uC for 2 hr.
Excess ovalbumin was removed by at least 4 rounds of
ultrafiltration using Amicon Ultra
TM 4 100,000 MWCO ultrafil-
tration units (Millipore Corp.). Each QD-streptavidin conjugate
contains an average of 10 molecules of surface-bound streptavidin
(Quantum Dot Corp.). Thus, a 1 nM solution of QD-streptavidin
conjugates bound to biotinylated ovalbumin, as used for priming
DCs in vitro, contains 10 nM ovalbumin, which is equivalent to
0.5 mg/ml of ovalbumin.
In vitro dendritic cell culture
Dendritic cells were cultured from tibial and femoral bone
marrow extracts of 8–12 week old mice as described [39]. Briefly,
the bone marrow extracts were cultured in non TC-treated
polystyrene culture dishes (Corning
TM) using IMDM (Lonza
TM)
substituted with 10% fetal calf serum (FCS; Hyclone Inc.), ,1,000
units/ml (20 ng/ml) recombinant mouse granulocyte/macro-
phage colony stimulating factor (GM-CSF; Pharmingen
TM), 100
units/ml penicillin, and 100 mg/ml streptomycin. DCs were
harvested between six and ten days of culture and used in
experiments. For flow cytometry of QD
+ cells, harvested DCs were
incubated in QD-containing medium (2 nM QD in RPMI
substituted with 10% FCS), for 30 min at 37uC, and subsequently
labeled with FITC-conjugated anti-mouse CD11c (Pharmin-
Figure 8. Activation of OT-II T cells in vivo by DCs pulsed with
QD
ova. (A, B, and C) CD69 upregulation in OT-II T cells following
immunization withCFA containing either 50 mg free ovalbumin (A), QD
ova
(B), or CFA alone (C). CD69 expression, evaluated 18 hr after immuniza-
tion, was similar with free ova (,6067%, n=3 experiments) and with
QD
ova (,6566%, n=3). (D–I) Proliferation of naı ¨ve OT-II T cells in draining
lymph nodes of C57BL/6 mice s.c. injected with varying doses of either
free ovalbumin (D–F, light gray), or ovalbumin conjugated to QDs (G–I,
d a r kg r a y )i n c l u d e di n5 0ml of CFA. Total amount of ovalbumin delivered
in free form or conjugated to QDs is indicated. (J, K, and L) IFN-c
expressioninmiceadoptivelytransferredwithOT-IITcellsandimmunized
with CFA containing 50 mg free ovalbumin (J) or conjugated with QDs (K),
or CFA alone (L). IFN-c expression was evaluated 4 days after
immunization. In three separate experiments, immunization with
QD
ova+CFA showed 2.460.6 greater upregulation of IFN-c, compared to
immunization with ovalbumin+CFA (p,0.05).
doi:10.1371/journal.pone.0003290.g008
Quantum Dot Uptake by DCs
PLoS ONE | www.plosone.org 9 September 2008 | Volume 3 | Issue 9 | e3290gen
TM), PE-conjugated anti-mouse CD11b (Ebioscience
TM)To
induce maturation, DCs were incubated with 1 mg/ml lipopoly-
sachharide (LPS) (Sigma-Aldrich Inc.) for 12–16 hr, and matura-
tion was verified by upregulation of MHC class-II (PE-conjugated
anti-mouse MHC-II; Pharmingen
TM) and CD86 (PE-conjugated
anti-mouse CD86; Pharmingen
TM).
In vitro imaging of DCs, quantification of QD uptake, and
vesicular dynamics
For in vitro imaging, bone marrow-derived DCs were plated on
cover glass chambers, and incubated with 2 nM QD-containing
medium. Unless otherwise mentioned, temperature was main-
tained at 37uC by perfusing temperature-controlled PBS below the
cover slip. For assessment of QD-toxicity in DCs propidium iodide
(Calbiochem
TM) staining was used. Fluorescence and DIC images
were acquired with a Zeiss Axiovert 35 microscope using a 406
1.30 n.a. oil-immersion objective, equipped with a temperature
controller. Higher resolution images were acquired with a custom-
built video-rate two-photon microscope based on a Olympus
BX50 confocal laser-scanning system, equipped with a titanium-
sapphire femtosecond laser (Tsunami, Spectra-Physics) tuned to
780 nm, photomultiplier tubes for detection, and a 6061.10 NA
water-immersion objective as previously described [40]. Every
image acquired was an average of 15 video-rate frames (acquired
at a rate of 30 frames/s using Metamorph
TM software (Universal
Imaging / Molecular Devices) and Video Savant (IO Indus-
tries
TM). Metamorph
TM was used to create time-lapse videos from
sequential two-photon images, and to observe and analyze QD
uptake and the trafficking of QD-containing endosomes inside
DCs. Images were acquired at a spatial resolution of 4.5 pixels/
mm using 110 mW mean laser power for quantification of QD
uptake, and at a spatial resolution of 12 pixels/mm for measure-
ment of kinetics of QD-containing vesicles. For evaluation of
antigen uptake in immature and mature DCs, QD-fluorescence
intensity was measured over time. After background subtraction,
intensities were normalized to the intensity measured 400 s after
incubation of DCs in QD-containing medium. The linear slopes of
intensities were measured to quantify rate of uptake of QDs by
DCs. Velocities and displacements of individual vesicles were
measured from unprocessed sequential two-photon images taken
at intervals of 700 ms. Normalized displacements of individual
vesicles were plotted to depict trajectories. For experiments
involving temperature-variation of vesicular dynamics, tempera-
tures were varied between 23uC and 37uC. Q10 was calculated as
Q10=10
DlogV, where DlogV is the change in the value of
log10velocity for a 10uC rise in temperature. To observe the
effects of cytoskeletal inhibitors on uptake of QDs, bone marrow-
derived DCs were labeled with 10 mM CFSE (Invitrogen
TM) for
15 min at 37uC, and subsequently treated with calyculin A
(Sigma-Aldrich
TM; 200 nM for 20 min), cytochalasin D (Sigma-
Aldrich
TM;1 mM for 1 hr), or nocodazole (Sigma-Aldrich
TM;
1 mM for 1 hr). These DCs were then incubated with 2 nM QD-
containing medium at 37uC in the maintained presence of each of
the reagents at the same concentration as used for pre-treatment.
Using Metamorph
TM QD-fluorescence and CFSE-fluorescence
were measured within regions containing .5 cells after 10 min of
incubation. Fluorescence intensity was normalized to intensity of
CFSE and has been presented as a ratio of QD-fluorescence
intensity of untreated control DCs. To observe the effects of
cytoskeletal inhibitors on vesicular motion, bone marrow-derived
DCs were first allowed to take up QD for 30 min at 37uC, and
subsequently treated with calyculin A (200 nM), cytochalasin D
(1 mM), or nocodazole (1 mM) during imaging. For lysosomal co-
localization, harvested DCs were cultured overnight in glass-
bottom culture dishes (Mattek
TM), incubated with 2 nM QD-
containing medium for varying times at 37uC. Subsequently, DCs
were fixed with 2% paraformaldehyde in PBS for 30 min at 4uC,
and then stained with 20 mg/ml FITC-conjugated anti-mouse
LAMP-2 (Pharmingen) for 2 hr at 4uC to stain lysosomes. DCs
were washed with PBS, dehydrated in 100% ethanol, mounted
using Vectashield
TM hardest mounting medium (Vector Labs),
and left overnight at 4uC before imaging. To observe the effects of
cytoskeletal inhibitors on F-actin organization and QD-uptake,
bone marrow-derived DCs were treated with cytochalasin D,
nocodazole, or calyculin A, and then incubated with 2 nM QD-
containing medium for 15 min at 37uC in the maintained
presence of these reagents, as described earlier. Subsequently
these DCs were plated on glass-bottom culture dishes, fixed with
4% paraformaldehyde and stained with 50 mg/ml FITC-phalloi-
din for 1 hr at room temperature. These samples were washed
with PBS, dehydrated in 100% ethanol, mounted using Vecta-
shield
TM hardest mounting medium (Vector Labs), and left
overnight at 4uC before imaging. Fixed DCs were imaged using
a Zeiss LSM-510 confocal microscope equipped with a Zeiss
TM
PlanApochromat
TM 6361.40 N.A. oil-immersion objective.
In vivo imaging of DC and determination of DC
phenotype
BALB/c mice were s.c. injected in lower flank with 100 nmol
CFSE (green) and 20 pmol QD (red) included in 50 ml of complete
Freund’s adjuvant (CFA, Sigma
TM). Draining inguinal and
brachial nodes from injected mice were harvested 24 hr later
and observed using two-photon microscopy as described [10].




TM), perfused with oxygenated RPMI
(Hyclone Inc.) maintained at 37uC, and observed using two-
photon microscopy. Images of several z sections (each an average
of 15 frames acquired at 30 frames/s) at varying distances of
separation were combined to create individual 3D time-points
using Metamorph
TM. For locating DCs with respect to B cell
follicles, mice were adoptively transferred with MACS
TM
magnetic separation chromatography-enriched (Miltenyi Biotec.)
B cells from BALB/c mice labeled with 25 mM 7-amino-4-
chloromethylcoumarin (CMAC, blue; Molecular Probes
TM /
Invitrogen
TM) for 45 min at 37uC; 24 hr later these mice were
s.c. injected with 100 nmol CFSE (green) and 20 pmol QD (red)
included in 50 ml CFA. 24 hr after injection, draining lymph
nodes were harvested for two-photon imaging. DCs were
recovered from lymph nodes for flow cytometry, as described
[41]. Briefly, lymph nodes from injected mice were harvested
24 hr after s.c. injection of dye-CFA mixture, digested with 1 mg/
ml Collagenase, Type IV (Worthington Biochemical) for 30 min at
37uC in DMEM substituted with 2% FBS. Cells were subsequently
labeled with PE-conjugated anti-mouse CD11c (Ebioscience
TM),
PE-conjugated anti-mouse GR-1 (Ebioscience
TM), or PE-conju-
gated anti-mouse CD8a (Ebioscience
TM), fixed with 2% parafor-
maldehyde in PBS, and analyzed by flow cytometry using
Facscalibur
TM flow cytometer (BD Biosciences).
Electron microscopy
Harvested DCs were cultured overnight in glass-bottom culture
dishes (Mattek
TM), incubated with 2 nM QD-containing medium
for varying times at 37uC, and processed as described [23]. Briefly,
DCs were fixed with 2% glutaraldehyde (Electron Microscopy
Sciences) in 0.1 M sodium cacodylate (Ted Pella
TM) buffer
(pH 7.3) for 20 min, washed with 0.1% cacodylate buffer, and
postfixed with 1% osmium tetroxide (Electron Microscopy
Sciences) solution for 30 min. Subsequently, the DCs were
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In vitro T cell proliferation assay
DCs (,4610
5 cells) were incubated with varying concentra-
tions of ovalbumin or QD
ova in U-bottom polystyrene tubes
(Fisher Scientific
TM). Antigen-pulsed DCs were incubated 6 hr
later with 1 mg/ml LPS for 12–16 hr. CD4
+ T cells were purified
from spleen and lymph nodes of DO11.10 mice by depleting
CD8
+ T cells, B cells, NK cells, DCs, macrophages, granulocytes,
and RBCs using MACS
TM magnetic cell separation kit (Miltenyi
Biotec.). Subsequently, the T cells were labeled with 4 mM
carboxyfluorescein diacetate succinimidyl ester (CFSE) (Molecular
Probes
TM/Invitrogen
TM)a t3 7 uC for 10 min and ,2610
6 cells (5
T cells per DC) were put into each U-bottom tube containing
antigen-pulsed or control DCs in T cell medium (RPMI, 10%
FCS, 1 mM sodium pyruvate, 1% non-essential amino acids, 1%
l-glutamine, 50 mM b-mercaptoethanol, 100 units/ml penicillin,
and 100 mg/ml streptomycin). After 72–96 hr at 37uC T cells
were harvested and stained using PE-conjugated anti-mouse
DO11.10 clonotypic T cell receptor (KJ1-26) antibody (Pharmin-
gen
TM). CFSE counts were gated on KJ1-26
+ cells and CFSE
dilution was analyzed using flow cytometry to measure prolifer-
ation due to T cell activation. T cell activation was measured in
terms of an activation index (AI) using Equation 1, derived as
described in Methods S1. M1 through M7 are the cumulative
counts of T cells within the gates M1 through M7, shown in
Figure 6A–6C. For comparison and evaluation of varying antigen
doses, the activation indices were normalized to the activation















In vivo T cell proliferation assay
T cells from DO11.10 (ova peptide
323–339/I-A
d) or OT-II mice
(ova peptide
323–339/I-A
b) were enriched using MACS
TM as
described above and labeled with 4 mM CFSE at 37uC for
15 min. ,4610
6 CFSE-labeled cells were adoptively transferred
into BALB/c (for DO11.10 T cells) or C57BL/6 (for OT-II T
cells) recipients, and allowed to equilibrate for 24 hr. Subsequently
the recipient mice were s.c. injected with varying dose of
ovalbumin or QD
ova, or QDs included in 50 ml CFA, or CFA
alone in the lower flank. Lymphocytes were recovered from lymph
nodes and spleens harvested 2–4 days later. Harvested lympho-
cytes from BALB/c recipients were stained with PE-conjugated
anti-mouse KJ1-26 antibody (Pharmingen) and analyzed for
proliferation using flow cytometry by gating on KJ1-26. Harvested
lymphocytes from C57BL/6 recipients were stained with PE-
conjugated Vb5.1/5.2 and APC-conjugated Va2, and analyzed
for proliferation using flow cytometry by gating on Vb5.1/5.2 and
Va2. T cell activation was measured in terms of activation index
(AI) using Equation 1 with five terms.
Imaging ova-specific T cell-DC interactions
T cells from DO11.10 mice were labeled with blue CMAC
(20 mMa t3 7 uC for 45 min) or green CFSE (10 mMa t3 7 uC for
15 min) and ,4610
6 cells were adoptively transferred into
BALB/c recipients. 24 hr later mice were s.c. injected on one
flank with QD
ova (containing 50 mg ovalbumin), and on the
opposite flank with QD included in 50 ml complete Freund’s
adjuvant. Lymph nodes were harvested 18 hr later and imaged
using two-photon microscopy, as described earlier. In separate
experiments, mice were immunized with QD
ova or QD, and 12 hr
later adoptive transferred with blue CMAC-labeled T cells.
Lymph nodes were harvested 8 hr after adoptive transfer of T
cells and imaged using two-photon microscopy.
Assessment of IFN-c production in T cells in immunized
mice
T cells from OT-II mice (expressing CD45.2) were enriched as
described above, and labeled with 4 mM CFSE at 37uC for
15 min. ,2610
6 CFSE-labeled cells were adoptively transferred
into congenic CD45.1-expressing BL6 recipients, and allowed to
equilibrate for 24 hr. Subsequently, the recipient mice were s.c.
injected with 50 mg ovalbumin or QD
ova, in both cases in 50 ml
CFA. Lymphocytes were harvested from draining inguinal lymph
nodes or control mesenteric lymph nodes 4 days after immuni-
zation. Harvested lymphocytes were re-stimulated with PMA and
ionomycin in vitro for 6 hr. For the last 2 hr BD
TM Golgistop
TM
was added to the medium. Subsequently, lymphocytes were
stained with PE-conjugated anti-mouse CD45.2 (Ebioscience),
fixed using BD
TM cytofix-cytoperm
TM cytokine staining kit, and
labeled with APC-conjugated anti-mouse IFN-c (Ebioscience) or
isotype control. Labeled cells were assessed for IFN-c production
by gating on CD45.2
+ cells.
Supporting Information
Methods S1 Equipment and Settings, Calculation of T cell
activation index (AI)
Found at: doi:10.1371/journal.pone.0003290.s001 (0.07 MB
DOC)
Figure S1 Quantum dots are not toxic to DCs. DCs were
incubated with 10 nM QD 525-Streptavidin conjugate for
48 hours, stained with 20 mg/ml of propidium iodide, and
assessed for toxicity using flow cytometry. Histograms showing
propidium iodide staining in untreated cells (green), QD-treated
cells (red), and cells fixed with 2% glutaraldehyde (black). Isotype
control has been shown in gray. While fixed DCs were ,100%
PI+, ,15–20% of QD-treated DCs were PI+, comparable to
untreated DCs. Thus QDs did not show toxicity at a concentration
of 10 nM, higher than any of the concentrations used in our
experiments
Found at: doi:10.1371/journal.pone.0003290.s002 (0.37 MB TIF)
Figure S2 Flow cytometry profile of cells that endocytosed QDs.
Bone marrow-derived cells were incubated for 30 min with 2 nM
QD at 37 mC, then washed and stained with (A) FITC-conjugated
anti-CD11c or (B) FITC-conjugated anti-CD11b, and analyzed by
flow cytometry by gating on the corresponding markers as shown
in figure. ,70% QD+ cells were CD11c+, and ,75% QD+ cells
were CD11b+.
Found at: doi:10.1371/journal.pone.0003290.s003 (0.39 MB TIF)
Figure S3 Confocal images showing effects of cytoskeletal
inhibitors on F-actin organization and QD-uptake by DCs. DCs
were either (A–C) untreated, or treated with (D–F) cytochalasin D
(1 mM for 1 hr at 37uC), (G–I) nocodazole (1 mM for 1 hr at
37uC), or (J–L) calyculin A (200 nM for 20 min at 37uC), and
incubated with media containing 2 nM QD (red) for 20 min in the
maintained presence of these reagents. Subsequently, these DCs
were fixed and stained with FITC-phalloidin to label F-actin
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real-time two-photon imaging. Scale bar=10 mm.
Found at: doi:10.1371/journal.pone.0003290.s004 (3.51 MB TIF)
Figure S4 QDs in subcapsular sinus of draining lymph nodes.
DCs were labeled in situ by subcutaneously injecting EYFP-
CD11c mice with QDs included in 50 ml CFA. Draining lymph
nodes were harvested 4 hrs later for imaging. Subcapsular fibers
appear blue due to second harmonics. (A) QDs (red) are trapped
inside vessels in the capsule and are presumably taken up by
subcapsular DCs (green) and macrophages. (B, C) Z sectional
views of the capsule show that QDs are not yet present inside the
node below the capsule. Scale bar=20 mm.
Found at: doi:10.1371/journal.pone.0003290.s005 (5.15 MB TIF)
Figure S5 Phenotypic profile of DCs observed by flow
cytometry. Phenotypic markers are indicated on the Y-axis of
each plot. Distribution of QD+ and CFSE+ cells (percent) for each
phenotypic marker is shown on the graph.Note the similarity in
distribution of QD+ and CFSE+ cells for each phenotypic marker.
Found at: doi:10.1371/journal.pone.0003290.s006 (0.86 MB TIF)
Figure S6 In vivo T cell response at different times following
immunization. BALB/c mice were adoptively transferred with
,4610
6 CFSE-labeled DO11.10 T cells, and subsequently
immunized with 50 mg of ovalbumin included in 50 ml CFA.
Control and draining lymph nodes, and spleens were harvested
(A–C) 2 days, (D–F) 3 days, or (G–I) 4 days after injection, and
analyzed for T cell activation using flow cytometry. Day 2 (just
prior to egress of activated T cells) was chosen as the time point for
analysis of T cell activation.
Found at: doi:10.1371/journal.pone.0003290.s007 (0.32 MB TIF)
Video S1 QD-labeled DCs in vitro
Found at: doi:10.1371/journal.pone.0003290.s008 (5.34 MB AVI)
Video S2 QD-uptake by DCs in vitro
Found at: doi:10.1371/journal.pone.0003290.s009 (7.53 MB AVI)
Video S3 Fusion of QD-containing vesicles inside DCs
Found at: doi:10.1371/journal.pone.0003290.s010 (2.56 MB AVI)
Video S4 Vesicles jiggling inside a single DC
Found at: doi:10.1371/journal.pone.0003290.s011 (8.19 MB AVI)
Video S5 Effect of cytochalasin D on vesicular motion
Found at: doi:10.1371/journal.pone.0003290.s012 (7.58 MB AVI)
Video S6 Effect of nocodazole on vesicular motion
Found at: doi:10.1371/journal.pone.0003290.s013 (6.22 MB AVI)
Video S7 Effect of calyculin A on vesicular motion
Found at: doi:10.1371/journal.pone.0003290.s014 (10.30 MB
AVI)
Video S8 In situ QD and CFSE-labeled DCs inside draining
lymph nodes
Found at: doi:10.1371/journal.pone.0003290.s015 (4.61 MB AVI)
Video S9 Localization of in situ-labeled DCs inside draining
lymph nodes relative to B cell follicles
Found at: doi:10.1371/journal.pone.0003290.s016 (4.15 MB AVI)
Video S10 Ova-specific T cells alongside QD-labeled DCs
inside lymph nodes
Found at: doi:10.1371/journal.pone.0003290.s017 (7.69 MB AVI)
Video S11 Ova-specific T cells cluster around QD
ova-labeled
DCs inside lymph nodes
Found at: doi:10.1371/journal.pone.0003290.s018 (4.94 MB AVI)
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